MoneyWorks4Me

Theta Pharmaceuticals Ltd (SYNCOM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533157 NSE: SYNCOM Pharmaceuticals & Drugs | Small Cap | Theta Pharmaceutical Share Price

₹4.12 0.00 (0.00%)

As on 28-Jun'21 18:01

Theta Pharmaceuticals Ltd (SYNCOM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533157 NSE: SYNCOM Pharmaceuticals & Drugs | Small Cap | Theta Pharmaceutical Share Price

₹4.12 0.00 (0.00%)

As on 28-Jun'21 18:01

Key Metrics
Valuation Multiples
Market Cap
₹16 Cr.
Current Price
₹4.1
52-Week Low / High
₹4 / 4
TTM EPS
₹-19.6
TTM Sales
₹41.5 Cr.
Book Value per Share
₹2.6
P/E Ratio
0.00
Industry PE
54.8
Price to Book (P/B)
1.57
Price to Sales (P/S)
0.40
EV/EBITDA
-8.49
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-157.91%
Return on Capital Employed (ROCE)
-103.84%
Return on Assets (ROA)
-81.79%
Operating Profit Margin
-12.5%
Net Profit Margin
-188.38%
Gross Profit Margin
-12.2%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
61.26%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
0.13%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-30 Cr.
Equity
₹40 Cr.
Face Value
₹10
All Time Low / High
₹0.65 / 162.40

Theta Pharmaceuticals stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % ⓘ-0.4%-0.5%-45.7%-94.8%-37.7%-66.7%-54.3%-24.1%-29.5%-29.6%-
Value Creation
Index ⓘ
-1.0-1.0-4.3-7.8NANANANANANA-

Growth Parameters ⓘ

Sales ⓘ61.962.952.841.564.1201.81.134.92
Sales YoY Gr.-1.7%-16%-21.4%54.4%-68.9%-90.8%-39.3%172.1%61.3%-
Adj EPS ⓘ-1-0.9-9.3-7.5-2.9-2.9-1.2-7.6-15.2-17.1-1.1
YoY Gr.-NANANANANANANANANA-
BVPS (₹) ⓘ40.639.8192.6-0.2-3.1-4.36.1-9.1-26.2-4.3
Adj Net
Profit ⓘ
-3.9-3.6-37-30.1-11.4-11.7-4.9-2.7-5.4-6.1-5
Cash Flow from Ops. ⓘ11.40.23.95.71.3-0.12.3-5.3-2.1-1.1-
Debt/CF from Ops. ⓘ2.5152.36.74.418.1-271.310.4-2.5-9.2-20.6-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ-24.6%-40.3%38.6%61.3%
Adj EPS ⓘNANANANA
BVPSⓘ-195.3%NANANA
Share Price -5.9% - - -

Key Financial Parameters ⓘ

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity % ⓘ
-2.4-2.2-31.3-69.5-239.2176.13335.41016.8977.4
Op. Profit
Mgn % ⓘ
2.51-4.3-12.4-2.9-9.2-179.1-126.1-67.1-65.2-164.9
Net Profit
Mgn % ⓘ
-6.3-5.8-70.1-72.4-17.8-58.7-268-241.4-178.7-124.8-243
Debt to
Equity ⓘ
0.20.20.32.4-26.5-1.9-1.46.2-6-2.4-
Working Cap
Days ⓘ
5434594804552233639131,365731559531
Cash Conv.
Cycle ⓘ
2102031881066-63-30-209123122-1,340

Valuation of Theta Pharmaceutical - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18
Sales134.93204.33191.58191.17123.9055.1641.53
Operating Expenses ⓘ + 129.95196.64194.26189.34123.1557.4146.78
Manufacturing Costs11.6110.1415.9110.0915.713.944.69
Material Costs99.32170.49158.38158.8889.1737.6824.20
Employee Cost 8.938.439.728.178.978.8310.30
Other Costs ⓘ 10.097.5810.2512.219.306.957.59
Operating Profit ⓘ 4.987.69-2.681.830.74-2.24-5.25
Operating Profit Margin (%) 3.7%3.8%-1.4%1.0%0.6%-4.1%-12.6%
Other Income ⓘ + 4.042.263.072.772.982.280.44
Exceptional Items ⓘ 00000-91.75-69.41
Interest ⓘ 2.503.684.194.573.323.100.28
Depreciation ⓘ 2.322.293.775.354.644.613.74
Profit Before Tax ⓘ 4.203.99-7.57-5.32-4.23-99.42-78.24
Tax ⓘ 0.86-0.02-3.21-1.53-0.807.910
Profit After Tax 3.354.01-4.36-3.79-3.43-107.32-78.24
PAT Margin (%) 2.5%2.0%-2.3%-2.0%-2.8%-194.0%-188.0%
Adjusted EPS (₹)0.81.0-1.1-1.0-0.9-26.9-19.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%
PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18

Equity and Liabilities

Shareholders Fund + 183.23190.53197.57198.06202.8188.6210.47
Share Capital ⓘ 40404040404040
Reserves ⓘ 143.23150.53157.57158.06162.8148.62-29.53
Debt +22.1730.6835.8927.5829.9622.8318
Long Term Debt7.8511.6111.2712.8610.708.344.76
Short Term Debt14.3319.0724.6214.7219.2614.4913.24
Minority Interest0000000
Trade Payables26.5043.5918.976.227.4413.0721.34
Others Liabilities ⓘ 0.454.174.59-2.42-4.055.9211.05
Total Liabilities ⓘ 232.35268.97257.03229.44236.16130.4460.87

Fixed Assets

Net Fixed Assets ⓘ +16.0525.6628.1923.4720.7020.0816.48
Gross Block27.2539.1245.3645.7046.8423.9724.10
Accumulated Depreciation11.2013.4617.1722.2326.143.897.62
CWIP ⓘ 1.08000000
Investments ⓘ 4.02000000
Inventories66.5119.4912.2113.3113.3510.809.53
Trade Receivables106.07175.99157.22152.31164.6269.6916.83
Cash Equivalents 0.451.118.390.851.400.490.56
Others Assets ⓘ 38.1746.7251.0239.4936.0929.3717.47
Total Assets ⓘ 232.35268.97257.03229.44236.16130.4460.87
PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18
Cash Flow From Operating Activity ⓘ + -199.77-1.180.96-0.61-7.984.185.65
PBT ⓘ 3.344.01-4.36-5.32-4.23-99.42-78.24
Adjustment ⓘ 5.395.905.268.887.0597.5773.18
Changes in Working Capital ⓘ -208.5-11.090.06-3.89-10.596.9110.71
Tax Paid ⓘ 000-0.27-0.20-0.900
Cash Flow From Investing Activity ⓘ + 6.06-3.505.065.939.384.86-0.97
Capex -1-11.90-6.330.250.07-2.44-0.13
Net Investments 04.020-1.01-1.4100
Others ⓘ 7.064.3811.396.6910.717.29-0.83
Cash Flow From Financing Activity ⓘ + 104.575.351.25-12.88-0.93-9.62-4.85
Net Proceeds from Shares ⓘ 0000000
Net Proceeds from Borrowing ⓘ 0000000
Interest Paid ⓘ -2.48-3.68-4.19-4.57-3.32-2.87-0.02
Dividend Paid ⓘ 0000000
Others ⓘ 107.069.025.43-8.312.38-6.75-4.83
Net Cash Flow ⓘ -89.130.677.28-7.560.47-0.59-0.16
PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18
Ratios
ROE (%)1.832.14-2.26-1.93-1.72-73.9-157.91
ROCE (%)3.263.59-1.49-0.33-0.4-55.4-103.84
Asset Turnover Ratio0.580.820.730.790.530.30.44
PAT to CFO Conversion(x)-59.63-0.29N/AN/AN/AN/AN/A
Working Capital Days
Receivable Days286.90251.90317.40295.50466.80768.10377.40
Inventory Days179.9076.8030.2024.4039.3079.2088.70
Payable Days97.407572.1028.902899.30259.50

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Theta Pharmaceuticals Ltd FAQs

The current trading price of Theta Pharmaceutical on 28-Jun-2021 18:01 is ₹4.12.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Jun-2021 the market cap of Theta Pharmaceutical stood at ₹16.48 Cr

The latest P/E ratio of Theta Pharmaceutical as of 27-Jun-2021 is 0.00.

The latest P/B ratio of Theta Pharmaceutical as of 27-Jun-2021 is -0.95.

The 52-week high of Theta Pharmaceutical is ₹4.33 and the 52-week low is ₹3.95.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Theta Pharmaceutical is ₹1.86 ( Cr.) .

Data is not available for this company.

The key valuation ratios of Theta Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

No data found

About Theta Pharmaceuticals Ltd

The Company was originally incorporated as Syncom Healthcare Limited on July 29, 2002 by Registrar of Companies, Maharashtra, Mumbai. The Certificate for Commencement of business was granted on August 2, 2002. The company has been promoted by Ajay Bankda & Jyoti Bankda. The company was formed for manufacturing, marketing & trading of pharmaceuticals formulations under its own brands in Ethical, OTC, Generic and Herbal market segment.

Initially it started its journey with the marketing of the pharmaceuticals products manufactured by others under its own brand and in year 2006, the company set up a State of Art manufacturing unit at Dehradun in Uttarakhand. The unit was commissioned in November, 2006. During the year ended March 31, 2007, the net profit before tax & extra-ordinary items, of the Company increased to Rs.331.38 lakh from Rs.32.20 lakh during the year ended March 31, 2006 due to commencement of manufacturing of the various products in its own manufacturing unit and marketing through a strong distribution network.

SHL started as a marketing Company, which was outsourcing its requirement of finished products (Under Its Own Brand And Drug License) from other formulation manufacturing units based in and around Indore. Presently also SHL is outsourcing some of its requirement of finished products. With these companies, Syncom has a purchase and sale arrangement where the supplier unit is manufacturing SHL’s products on SHL’s specification and under SHL’s quality control under which SHL controls the quality of raw material, their sourcing by the supplier as well as production in the units of these suppliers. The manufactured goods, manufactured for SHL are sold to SHL on pre-decided order prices for each formulation product so manufactured.

To cater the diversified and increased demand the Company planned to set up its own pharmaceutical manufacturing facilities. Accordingly, the company set up a manufacturing facility at Dehradun in the state of Uttrakhand, which is a Tax free & duty free Zone. The Company set up its Plant at Dehradun and it started the commercial production in November, 2006. Presently Company is Manufacturing, Marketing and Distributing its Pharmaceutical Formulations under own Brands of Ethical, OTC, Generic and Herbal market segment.

Product range of the company:

Syncom has presence in Pharmaceuticals Formulations which can be categorized in 4 broad categories i.e. Generic, OTC, Ethical and Herbal. The company manufactures a range of products such as Ethical drugs, Generic drugs, over the counter drugs (OTC) and Herbal formulations in various dosage forms and markets them under the trade mark ‘Syncom’ which is a registered trademark in the name of Syncom Healthcare Limited. The company also undertakes contract manufacturing for large variety of pharmaceutical formulations for a number of other pharmaceutical companies of national and international repute such as Lupin Limited, Nicholas Piramal India Ltd, Galpha Laboratories Limited, Percos India Pvt. Ltd etc. (under their own brands) located in India.

The company manufactures various dosage forms, which include tablets, capsules, eye/ear drops, ointment and creams and dry syrups. The company has an established product-marketing network covering both metro and minimetro cities, which enable it to reach the existing and potential customers through the network of distributors and dealers spread across the country. For the purpose of marketing the various products, the Company’s business has been categorized as Branded Generic Division, Over the Counter (OTC), Ethical division and Contract Manufacturing Division.

The Company is producing more than 130 products in Generic segment which includes CTZ, Profeed, Nimjet, Divoron, Gentijet, Ciprojet, etc.

Apart form Generic, the Company has developed presence in OTC Segment. The Company is producing more than 40 products in this segment which include Fastac, Q-coril, Triple action, Pandrop, Syncom Gripe Water, etc. Having built-up a presence in Generic & OTC segment and as a measure to expand and grow, the Company has also entered into Ethical segment. Syncom has developed more than 20 products in this segment which includes Fresca, Flusa, Nutone, Busera, etc.

Syncom is also having presence in Herbal segment with around 25 products which includes Patton, Attom, Narisudha, Salony Cream, etc.

Milestones:

  • 2002 - Incorporation of Syncom Healthcare Limited
  • 2002 - Syncom Healthcare Limited started marketing operations
  • 2005 - Commenced setting up of manufacturing facility at Selaqui, Dehradun
  • 2006 - Start of commercial production at Dehradun Industrial Unit for its own marketing
  • 2007 - Entered into agreement for Contract manufacturing with Lupin Limited, Galpha Laboratories, Nicholas Piramal, etc. Pharmaceutical Companies for manufacturing its various range of products.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now